Post-Viral Recovery
83
synergie
3
2,100
intermediate
May 17, 2026
Aperçu
The Post-Viral Recovery stack is designed for individuals experiencing persistent fatigue, immune dysregulation, and inflammatory symptoms following viral infections — including but not limited to long COVID, post-EBV syndromes, and chronic fatigue syndrome with viral triggers. The protocol increases Thymosin Alpha-1 frequency to 3x weekly (from the standard 2x) to provide more aggressive immune reconstitution. Ta1''s ability to restore T-cell subset ratios (CD4/CD8 balance), enhance dendritic cell maturation, and promote interferon production makes it the cornerstone of post-viral immune recovery. Clinical data from COVID-19 treatment showed Ta1 reduced mortality and improved T-cell counts in critically ill patients. LL-37 is the only human cathelicidin — an antimicrobial peptide produced by neutrophils, macrophages, and epithelial cells as a first-line defense against pathogens. Beyond direct antimicrobial activity (it disrupts bacterial and viral membranes), LL-37 modulates immune cell recruitment, promotes wound healing, and importantly, helps resolve chronic inflammation by promoting macrophage phenotype switching from M1 (pro-inflammatory) to M2 (resolving/repair). In post-viral syndromes, persistent M1-dominant inflammation drives ongoing symptoms; LL-37 may help break this cycle. BPC-157 at twice-daily dosing provides systemic anti-inflammatory support and gut healing — critical because many post-viral syndromes involve gut barrier disruption and microbial translocation that perpetuate immune activation. Its modulation of the nitric oxide system and multiple growth factor pathways creates a tissue-repair environment throughout the body. The three-peptide combination addresses post-viral recovery comprehensively: Ta1 restores immune competence, LL-37 resolves chronic inflammation and provides antimicrobial coverage, and BPC-157 repairs tissue damage and restores gut barrier function. This is classified as intermediate due to the three-compound regimen and the clinical complexity of post-viral conditions.
Protocole de dose
1,500 mcg
par dose
100 mcg
par dose
250 mcg
par dose
Objectifs & Preuves
Avertissements
- LL-37 is an antimicrobial peptide with emerging research for post-viral syndromes. Limited human data outside of wound healing. Thymosin Alpha-1 remains FDA Category 2 (restricted) in the US (approved abroad as Zadaxin).
Comments
Sign in to join the discussion
Avertissement : Ce stack est soumis par la communauté et est destiné à des fins de recherche uniquement. Peptide Contacts ne vérifie pas la sécurité ou l'efficacité des stacks soumis. Consultez toujours un professionnel qualifié de la santé avant d'utiliser tout protocole de péptides.